Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
about
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerThe importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic painDifferential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.Design, synthesis, in vitro cytotoxic activity evaluation, and apoptosis-induction study of new 9(10H)-acridinone-1,2,3-triazoles.Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine.Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.Evaluating Cytotoxicity of Hyaluronate Targeted Solid Lipid Nanoparticles of Etoposide on SK-OV-3 Cells.Raptor hunted by caspases.Caspase-mediated cleavage of raptor participates in the inactivation of mTORC1 during cell deathSignificance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinomaMonepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies
P2860
Q33947251-CD1110E2-3929-49B7-A807-F501A4EFBCC1Q35854002-02A6453B-17CC-405C-85B5-1150CF6421C9Q35992948-D67B848E-C148-4611-B5D4-3478CCEDEE64Q36820568-5CB3A0C5-D776-41BA-A84A-DCFCE1CC988DQ37117256-66FB0C66-024E-4570-962B-9E6D6BA7F1A4Q37609985-BC43477D-F23B-4B3A-B24D-A5543BF8ADA5Q38853487-66628421-6C12-495B-ABF2-82003689B623Q38975853-ED295A7C-10DD-4583-B09D-17974E12EA65Q38987013-62FF97A5-1EA3-4EA4-8E35-C48BF5D44323Q39593383-D65356FF-90AB-4D1D-9CE5-142B9138B237Q41877464-25A53695-9B64-43CC-B40A-E625B502C62EQ42268633-6D3E3F1B-0715-4344-8376-091E4D0A74ACQ54275299-D694FCBE-0D01-4F18-99E7-3E8676ECCA04Q58698452-CFBAF870-E238-4754-A329-42A14DD590DBQ58790039-DBEA83C0-C4F3-4F19-97BF-24377337029D
P2860
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@en
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@nl
type
label
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@en
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@nl
prefLabel
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@en
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@nl
P2093
P921
P1476
Inhibiting the mTOR pathway sy ...... through upregulation of c-Jun.
@en
P2093
Hiroaki Itamochi
Jun Naniwa
Junzo Kigawa
Kazunori Uegaki
Michiko Nonaka
Muneaki Shimada
Naoki Terakawa
Seiya Sato
Shinya Sato
Tasuku Harada
P304
P356
10.1158/1078-0432.CCR-11-0190
P407
P577
2011-05-24T00:00:00Z